Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
To investigate whether a reduced-dose dosing regimen (1x500mg semiannually) of rituximab (RTX) (Mabthera®) is non-inferior in patients with rheumatoid arthritis (RA) whose disease is in persistent low disease activity (LDA) or clinical remission (REM) (pLDA/pREM) as compared to the standard dosing regimen of 1x1000mg semi-annual infusions.
Epistemonikos ID: bd6e44b4eca2774fdf665b5d1eafbb4ea20abdc9
First added on: Mar 23, 2022